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IL-1 Signaling in Obesity-Induced Hepatic Lipogenesis
and Steatosis
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Abstract
Non-alcoholic fatty liver disease is prevalent in human obesity and type 2 diabetes, and is characterized by increases in both
hepatic triglyceride accumulation (denoted as steatosis) and expression of pro-inflammatory cytokines such as IL-1b. We
report here that the development of hepatic steatosis requires IL-1 signaling, which upregulates Fatty acid synthase to
promote hepatic lipogenesis. Using clodronate liposomes to selectively deplete liver Kupffer cells in ob/ob mice, we
observed remarkable amelioration of obesity-induced hepatic steatosis and reductions in liver weight, triglyceride content
and lipogenic enzyme expressions. Similar results were obtained with diet-induced obese mice, although visceral adipose
tissue macrophage depletion also occurred in response to clodronate liposomes in this model. There were no differences in
the food intake, whole body metabolic parameters, serum b-hydroxybutyrate levels or lipid profiles due to clodronate-
treatment, but hepatic cytokine gene expressions including IL-1b were decreased. Conversely, treatment of primary mouse
hepatocytes with IL-1b significantly increased triglyceride accumulation and Fatty acid synthase expression. Furthermore,
the administration of IL-1 receptor antagonist to obese mice markedly reduced obesity-induced steatosis and hepatic
lipogenic gene expression. Collectively, our findings suggest that IL-1b signaling upregulates hepatic lipogenesis in obesity,
and is essential for the induction of pathogenic hepatic steatosis in obese mice.
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Introduction
The prevalence of obesity represents a fully fledged epidemic as
greater than 300 million adults are clinically obese worldwide [1].
Obesity is a prominent risk factor for insulin resistance (IR), type 2
diabetes, non-alcoholic fatty liver disease (NAFLD) and other
metabolic disorders because it impairs systemic metabolic homeo-
stasis. A major hallmark of obesity is adipose tissue (AT)
dysfunction, which is characterized by a chronic state of low-
grade inflammation, and by a decreased ability of adipocytes to
efficiently store excess nutrients and lipids as triglycerides (TGs)
[1,2,3]. This in turn is thought to increase circulating free fatty
acids (FFAs) and ectopic lipid deposition within insulin sensitive
tissues, such as muscle and liver, causing IR. The intracellular
hepatic lipid accumulation and subsequent formation of lipid
droplets within hepatocytes can activate resident tissue macro-
phages, otherwise denoted as Kupffer cells (KCs), which release
pro-inflammatory cytokines, including TNF-a, IL-6 and IL-1b
[4,5,6]. This inflammation enhances NAFLD progression to
fibrosis, cirrhosis, chronic liver disease, and exacerbates IR
[4,5,6,7,8].
Recently, macrophage depletion techniques have been used to
determine the effects of macrophage function on insulin sensitivity.
Conditional macrophage ablation in combination with transgenic
and gene deletion mouse models have demonstrated that CD11c+
macrophages, Nlrp3-inflammasome components and pro-inflam-
matory cytokines promote glucose intolerance and IR in both diet-
induced obesity (DIO) and genetic mouse models of obesity
[9,10,11,12,13,14,15]. Drug-encapsulated liposome administra-
tion has been utilized to selectively deplete KCs and visceral
adipose tissue macrophages (VATMs) to improve glucose and
insulin sensitivity and reduce hepatic steatosis in DIO mouse
models [12,16,17]. Lastly, anti-cytokine therapy or pharmacolog-
ical blockade of pro-inflammatory cytokines has also been
successful in improving systemic glucose and insulin tolerance as
well as b-cell function in obese mice and human subjects
[14,18,19]. One such drug is Anakinra (Kineret), which is
recombinant IL-1Ra that blocks IL-1 signaling via the IL-1
receptor [18,20,21]. However, previous work utilizing clodronate
liposomes to deplete KCs in DIO mice have reported contradic-
tory conclusions regarding the involvement of KCs in obesity-
driven steatosis, clouding the roles of these cells in this syndrome
[12,22,23,24].
The present studies were designed to clarify this issue and
elucidate the mechanism by which KC-derived pro-inflammatory
cytokines regulate whole body and hepatic lipid metabolism in
obesity. We targeted KCs in vivo by intraperitoneal (i.p.)
clodronate liposome administration in two animal models of
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obesity: DIO and ob/ob mice. The results herein demonstrate that
clodronate liposome-mediated KC depletion, regardless of VATM
content in both DIO and ob/ob mice, abrogated hepatic steatosis
by reducing hepatic de novo lipogenic gene expression. Addition-
ally, we observed significant decreases in hepatic inflammation
and hypothesized that IL-1b may be responsible for the increased
TG accumulation in obese mouse livers. In agreement with this
hypothesis, IL-1b treatment increased hepatic lipid deposition and
Fas expression in primary mouse hepatocytes. Furthermore, the
pharmacological inhibition of IL-1 signaling by administration of
recombinant human IL-1Ra to DIO mice attenuated obesity-
induced hepatic steatosis and reduced hepatic lipogenic gene
expression. These data illustrate the importance of IL-1b in
obesity-driven hepatic steatosis, and suggest that liver inflamma-
tion controls hepatic lipogenesis in obesity.
Methods
Animals, Diets and Treatments
Wild type male C57Bl/6J and ob/ob mice were purchased from
Jackson laboratories (Bar Harbor, ME). Animals were fed ad
libitum with free access to water and housed in the University of
Massachusetts Medical School (UMASS) Animal Medicine facility
with a 12:12-h light-dark cycle. Animals were weighed weekly for
the duration of the diet study. Animals utilized for the clodronate-
encapsulated liposome and IL-1Ra studies were fed a high fat diet
(HFD, 45 kcal% fat; D12451; Research Diets) starting at 4 wks of
age for 13–14 weeks. 8-week-old ob/ob mice were fed a standard
chow diet (LabDiet PicoLab 5053). Liposome-encapsulated
clodronate (250 mg/kg) or an equivalent volume of PBS-liposomes
was administered twice i.p. with a three day interval over the
course of 6 days in the final week of the HFD-challenge or a week
prior to ob/obmouse tissue isolation. Mice were started on daily i.p.
injections of recombinant human IL-1 receptor antagonist (IL-
1Ra) (32 mg/kg) or saline (Anakinra; Amgen) starting after 9
weeks of HFD and 32 days prior to sacrifice. Intraperitoneal
glucose tolerance tests (IPGTTs) were performed as previously
described after 28 daily IL-Ra injections [25]. Measurements of
energy expenditure, respiratory exchange ratio, indirect calorim-
etry, and physical activity using metabolic cages (TSE Systems,
Bad Homburg, Germany) were performed by the UMass Mouse
Metabolic Phenotyping Center. At experimental completions,
mice were fasted for 6 hours at the start of the light cycle and then
euthanized with CO2 inhalation and cervical dislocation. All of the
experiments were performed in accordance with protocols
approved by the Institutional Animal Care and Use Committees
(IACUC) at UMass Medical School.
Sample Storage
Liver and VAT were harvested and snap frozen in liquid
nitrogen for RNA and protein or optimal cutting temperature
(OCT) compound for Oil-Red-O analysis. Blood was drawn via
the retro-orbital sinus into EDTA tubes; plasma was centrifuged at
10,000 rpm for 10 min and aliquotted. All of the samples were
stored at 280uC.
Primary cell isolation and culture
Anesthetized 8-week old WT mice were perfused via the inferior
vena cava as previously described [26]. Briefly, mice were perfused
with a 0.5 mM EGTA solution followed by enzymatic collagenase
digestion (Sigma) in 1 mM CaCl2. Hepatocytes were washed with
1 mM CaCl2 (3x) and separated by centrifugation. Primary
hepatocytes were seeded in 6-well plates. Before starting stimula-
tion experiments, hepatocytes were rested for 3 hours in M199
media containing 1% Penicillin/Streptomycin, 10% FA-free BSA,
2% FBS, Dexamethasone (100 uM), and Insulin (100 nM) at 37uC
and 5% CO2. Subsequently, culture media was replaced and cells
were maintained in M199 media containing Penicillin/Strepto-
mycin, Dexamethasone and Insulin. Insulin was present in all
experimental media to maintain the health of the primary
cultures. Cells were left untreated or treated with 10 ng/ml
recombinant IL-1b (Millipore) for 24 hours.
RNA isolation and quantitative RT-PCR
Liver and VAT were isolated, snap frozen in liquid nitrogen,
and stored at 280uC. Tissues were homogenized using the
gentleMACs Dissociator (Miltenyi Biotec) and isolated following
the manufacturers protocol (TriPure, Roche). Precipitated RNA
was treated with DNAse (DNA-free, Life Technologies) prior to
reverse transcription (iScript Reverse transcriptase, BioRad).
SYBR green quantitative PCR (iQ SYBR green supermix,
BioRad) was performed on the BioRad CFX97. Gene expression
was normalized to the ribosomal gene 36B4 and expressed relative
to the expression of PBS liposome- or saline-treated mice. The
internal loading control, 36B4, did not change with liposome or
IL-1Ra treatment. Melt curve analysis was performed to
determine the PCR reaction product specificity. Primer sequences
were designed with Primer Bank. Primer sequences are as follows:
36B4: 59-TCCAGGCTTTGGGCATCA-39, 39-CTTTAT-
CAGCTGCACATCACTCAGA-59, CD11c: 59-CTGGA-
TAGCCTTTCTTCTGCTG-39,39-GCACACTGTGTCC-
GAACTCA-59; F4/80: 59-CCCCAGTGTCCTTACAGAGTG-
39, 39-GTGCCCAGAGTGGATGTCT-59; IL1b: 59-
GCAACTGTTCCTGAACTCAACT-39, 39-
ATCTTTTGGGGTCCGTCAACT-59; TNFa: 59-
CAGGCGGTGCCTATGTCTC-39, 39-CGATCACCCC-
GAAGTTCAGTAG-59; IL-6: 59-TAGTCCTTCCTACCC-
CAATTTCC-39, 39-TTGGTCCTTAGCCACTCCTTC-59; IL-
1a: 59-GCACCTTACACCTACCAGAGT-39, 39- TGCAGGT-
CATTTAACCAAGTGG-59; NLRP3: 59-ATTACCCGCCCGA-
GAAAGG-39, 59-TCGCAGCAAAGATCCACACAG-39, FASn:
59-GGAGGTGGTGATAGCCGGTAT-39, 59-TGGGTAATC-
CATAGAGCCCAG-39, DGAT: 59-TCCGTCCAGGGTGG-
TAGT-39, 59-TGAACAAAGAATCTTGCAGACGA-39,
ELOV6: 59-GAAAAGCAGTTCAACGAGAACG-39, 59-
AGATGCCGACCACCAAAGATA-39, ACC2: 59-
GGAGGCTGCATTGAACACAAGT-39, 59-
TGCCTCCAAAGCGAGTGACAAA-39, PPARG2: 59-
ATGGGTGAAACTCTGGGAG-39, 59-GTGGTCTTCCAT-
CACGGAGA-39, SCD1: 59-TTCTTGCGATA-
CACTCTGGTGC-39, 59-CGGGATT-
GAATGTTCTTGTCGT-39, PPARa: 59-
AGAGCCCCATCTGTCCTCTC-39, 59-ACTGGTAGTCTG-
CAAAACCAAA-39, CPT1A: 59-GCTGCTTCCCCTCA-
CAAGTTCC-39, 59-GCTTTGGCTGCCTGTGTCAG-
TATGC-39, BAX: 59-AGACAGGGGCCTTTTTGCTAC-39,
59-AATTCGCCGGAGACACTCG-39, BAK: 59-
CAGCTTGCTCTCATCGGAGAT-39, 59-GGTGAA-
GAGTTCGTAGGCATTC-39.
Protein Analysis
Tissue pieces were homogenized in a Dounce homogenizer in
RIPA protein lysis buffer [50 mM Tris (pH 7.4), 0.1% SDS,
400 mM NaCl, 0.5% deoxycholate, 1% NP40,1 mM EDTA,
25 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride, and 10 mg/ml
of aprotinin and leupeptin. Primary hepatocytes were homoge-
nized in lysis buffer (150 mM NaCl, 2% SDS, and 2 mM EDTA,
IL-1 Signaling and Hepatic Triglyceride
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25 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride, and 10 mg/ml
of aprotinin and leupeptin. Samples were sonicated using a
microtip and protein content was quantified using a BCA protein
assay kit (Thermo Scientific). Proteins were resolved on a 10%
SDS-PAGE gel, transferred to a nitrocellulose membrane, blocked
with 5% non-fat milk in TBST (0.05% Tween 20 in Tris-buffered
saline), washed with TBST, and incubated with primary
antibodies overnight. The blots were washed with TBST, and a
horseradish peroxidase secondary antibody was applied. Proteins
were visualized using Western Lightening Plus ECL (PerkinEl-
mer). Primary antibodies used were Fas and b-Actin (Cell
Signaling; 1:1000 and 1:10,000).
Histology
Livers were isolated and fixed in 10% formalin, paraffin
embedded, and stained with hematoxylin and eosin (H&E) or
frozen in OCT and stained with Oil-Red-O. Images were taken
with an Axiovert 35 Zeiss microscope (Zeiss, Germany) equipped
with an Axiocam CCl camera at 10x or 20x magnification.
Non-Esterified Fatty Acid (NEFA) measurements
EDTA plasma was collected from the retro-orbital sinus after
isoflurane anesthesia. NEFA were measured with a colorimetric
assay (WAKO) using the manual procedure according to
manufacturer’s instructions.
Triglyceride measurements
Total hepatic TG content measurement was performed as
previously described [27]. Briefly, total lipids were extracted from
liver samples (100 mg) or primary hepatocyte cultures using a 2:1
mixture of chloroform and methanol. The organic layer was dried
overnight and reconstituted in a solution containing 60% butanol
and 40% of a 2:1 mixture of Triton-X114 and methanol. Total
TGs were measured with a colorimetric assay (Sigma) using the
manual procedure according to manufacturer’s instructions.
ELISA Assay
EDTA plasma was collected from the retro-orbital sinus after
isoflurane anesthesia. The exogenously administered IL-1Ra was
measured using specific ELISA recognizing human IL-1Ra (R&D
systems Inc.) and fasting insulin levels using a rat/mouse insulin
ELISA (Millipore). Both assays were measured in duplicate and
according to the manufacturers9 instructions.
Flow cytometry
The VAT stromal vascular fraction (SVF) was isolated by
digestion in HBSS, 2.5% BSA and 2 mg/mL collagenase for
45 minutes and strained through a 70 mm filter followed by red
blood cell lysis. Cells were blocked with mouse IgG in FACS buffer
(1% BSA/PBS). Cells were stained with antibodies directed
towards F4/80 (APC, ABD serotec), CD11b (Percp 5.5, BD),
Siglec F (PE, BD) and CD11c (V450, BD). The data were collected
on an LSRII flow cytometer (BD) and were analyzed with FlowJo
software. Samples were gated for scatter and single cells. Gates
were drawn based on fluorescence minus one (FMO) controls. A
total of 100,000 events were recorded.
Liposome Preparation
Cholesterol (16 mg) and phosphatidylcholine (172 mg) (Sigma-
Aldrich) were dissolved in chloroform in a round-bottom flask.
The chloroform was evaporated at 37uC in a rotary evaporator
under vacuum until a thin lipid film formed. 2 g of dichlor-
omethylenediphosphonic acid disodium salt (clodronate) (Sigma-
Aldrich) were dissolved in 10 ml of PBS. The clodronate-PBS
solution or the control-PBS solution was added to the lipid film
and shaken at 4 g for 30 minutes. The solution was sonicated for
2 minutes at room temperature in a water bath sonicator (150
watts). The liposomes were washed and centrifuged at 20,000 g for
2 hours, and resuspended in 8 ml of PBS. An aliquot of each
liposome preparation was subjected to 1:2 phenol:chloroform
extraction to determine the incorporated clodronate concentration
within the liposomes and analyzed via liquid chromatography
mass spectroscopy on a Waters Acquity UPLC with a Phenom-
enex 2.16100 mm Synergi 4u Polar-RP 80A column. A standard
curve was created using QuanLynx and samples were then
quantified against this calibration curve.
Statistical Analysis
All of the values are presented as the mean 6 SEM. For all
experiments a student’s t-test for two-tailed distributions with
equal variances was used for comparison between 2 groups.
Differences less than p,0.05 were considered to be significant.
The area under the curve (AUC) for the IPGTT was calculated
using a student’s t-test after performing a baseline correction for
the basal glucose values for each individual mouse. All of the data
were entered into Microsoft Excel, and statistical analyses were
performed with Graph Pad Prism 6.0.
Results
Clodronate liposome-mediated KC depletion ameliorates
hepatic steatosis in both DIO and ob/ob mice
Resident tissue macrophages aid in tissue homeostasis, but
obesity can promote low-grade inflammation in insulin sensitive
tissues. Conflicting literature has complicated our understanding
of the role of KCs and hepatic inflammation in lipid homeostasis
in obese mouse livers [12,22,24,28]. Thus, we sought to investigate
the mechanism whereby KCs and KC-derived cytokines regulate
whole body and hepatic lipid metabolism in two mouse models of
obesity after clodronate liposome-mediated KC depletion. We
employed a 2-dose injection scheme of clodronate liposomes
(250 mg/kg) or an equivalent volume of control PBS liposomes to
deplete KCs in vivo. Liposomes were injected i.p. into DIO or ob/
ob mice every 3-days over the course of 6 days during the final
week of a 13-week HFD challenge. It has been established that
short-term diet-induced IR is caused by lipotoxicity, which occurs
after only 3 days of high fat feeding [29]. Chronic inflammation
emerges as a more dominant mechanism once obesity is
established by a long-term, 10-week high fat feeding [29].
Therefore, late phase injections were utilized in this study. We
observed no changes in the total animal body weight of PBS or
clodronate liposome-treated mice upon completion of the exper-
iments (Fig. 1).
Previous studies employing i.p. clodronate liposome adminis-
tration in DIO mice report inconsistencies in the ability to deplete
both KCs and VATMs from the liver and VAT, respectively
[12,24,28]. To first confirm the efficiency of macrophage depletion
within the VAT of the clodronate-treated DIO mice, we isolated
the VAT stromal vascular fraction (SVF) on day 6 from animals
that had been injected with clodronate or an equivalent volume of
PBS liposomes. Cells were characterized by flow cytometry
analysis and macrophages were identified as cells that were
positive for CD11b and F4/80 antigen and negative for the
eosinophil marker Siglec F [30,31]. In PBS liposome-treated DIO
animals, approximately 27% of Siglec F-negative SVF cells were
positive for both CD11b and F4/80 (Fig. 1A–B). However, in
IL-1 Signaling and Hepatic Triglyceride
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clodronate-treated DIO animals, this percentage decreased to
14%, which was a 45% decrease compared with PBS liposome-
treated mice. Moreover, the percentage of the M1-type inflam-
matory macrophage marker, CD11c, of the total SVF cells was
reduced 68% in clodronate-treated mice compared with PBS
liposome-treated mice (Fig. 1A–B; p,0.05). As assessed by qRT-
PCR, we observed an 82% and 65% decrease in F4/80 and
CD11c gene expression, respectively, in clodronate-treated DIO
mouse livers compared with control animals (Fig. 1D; p#0.01,
0.05). We also isolated subcutaneous AT (SAT), lung and spleen to
determine if clodronate-liposomes are capable of depleting
resident tissue macrophages within other tissues. We observed a
reduction in splenic macrophage content without affecting
macrophages present within the lungs or SAT of clodronate-
treated mice compared with PBS liposome-treated control mice
(data not shown). We also isolated SAT, lung and spleen to
determine if clodronate-liposomes are capable of depleting
resident tissue macrophages within other tissues. We also isolated
primary hepatocytes from clodronate-treated DIO mice via
perfusion and observe no changes in pro-apoptotic gene expres-
sion, indicating that the hepatocellular apoptosis pathway is
unaffected by clodronate liposome treatment (data not shown).
Taken together, these results indicate that both macrophages in
VAT and KCs in the liver of DIO mice were greatly reduced by
the clodronate treatments.
Figure 1. Clodronate liposomes effectively deplete KCs and VATMs of DIO mice.Wild type mice were fed a HFD for 13 weeks and injected
with 2 doses of clodronate liposomes (250 mg/kg) or PBS liposomes i.p. over 6 days with a 3-day interval. We observed no changes in the total animal
body weight of PBS liposome-treated mice (42.461.8 to 41.661.9) or clodronate-treated mice (44.0162.2 to 41.562.6). VAT SVF was isolated and
FACS analysis was performed. A.) Upper panels, PBS liposome-treated mice. Lower panels, clodronate-treated mice. Left panels, SiglecF-negative,
CD11b- and F4/80-positive cells. Right panels, CD11c-positive cells. Panels are representative of 6 animals per group. B.) Percentage of the total
number of cells counted for both CD11b- and F4/80-positive cells and CD11c-positive cells in the VAT of DIO mice. RNA was extracted and
quantitative RT-PCR was performed for standard macrophage markers (F480, CD11c) in C.) VAT and D.) liver of DIO mice. Values represent the mean
6 SEM. An unpaired student’s t-test was used for comparisons between groups. *P#0.05, **P#0.01.
doi:10.1371/journal.pone.0107265.g001
IL-1 Signaling and Hepatic Triglyceride
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Upon dissection of the mice, we noted a macroscopic reduction
in the steatotic appearance of the livers of clodronate-treated DIO
animals compared with PBS liposome-treated control mice. In
agreement with this observation, DIO mouse liver weights as a
percentage of total animal body weight were decreased by 19% in
clodronate-treated mice compared with PBS liposome-treated
mice (Fig. 2B; p#0.01). Clodronate-treated DIO mice displayed a
significant reduction of liver TGs when compared with PBS
liposome-treated mice, as observed microscopically by H&E and
Oil-Red-O staining (Fig. 2A). Quantitative analysis revealed that
KC depletion resulted in a 62% decrease in hepatic TG content in
clodronate-treated DIO mice compared with the PBS liposome-
treated controls (Fig. 2C; p#0.05). These data demonstrate that
clodronate-mediated KC and VATM depletion results in a
remarkable reduction in hepatic TG content and amelioration of
obesity-induced steatosis in DIO mice.
In order to determine whether these results would also apply to
a genetic model of obesity, we used the leptin-deficient ob/ob
mouse in a subsequent set of experiments. Unexpectedly, no
reduction in ob/ob mouse VATM content was observed after
clodronate treatment as assessed by either FACS analysis or RT-
PCR (Fig. 3A–C). Thus, clodronate treatment depleted VATMs in
the DIO mouse model of obesity, but not in ob/ob mice when
compared with their respective PBS liposome-treated controls.
However, we observed a 94% and 60% decrease in F4/80 and
CD11c gene expression, respectively, in ob/ob mouse livers after
clodronate treatment compared with PBS liposome-treated mice
(Fig. 3D; p#0.001, 0.05). These data illustrate that clodronate
administration can effectively and efficiently deplete KCs from the
livers of both DIO and ob/ob mice, whereas VATM depletion only
occurs in the DIO mouse model.
In spite of the fact that cell depletion due to clodronate was
restricted to KCs and not VATMs in the ob/ob mouse model, a
similar reduction in the steatotic appearance of the livers of
clodronate-treated ob/ob animals compared with PBS liposome-
treated animals was apparent (Fig. 4). In agreement with this
observation, ob/ob mouse liver weights as a percentage of total
body weight were decreased 30% in the clodronate-treated
animals compared with PBS liposome-treated animals (Fig. 4B;
p#0.01). Microscopic analysis of livers stained with H&E and Oil-
Red-O revealed a significant reduction of liver TGs in clodronate-
treated ob/ob mice compared with the PBS liposome-treated mice
(Fig. 4A). Quantification of hepatic TG content revealed that KC
depletion resulted in a 45% decrease in hepatic TGs in clodronate-
treated ob/ob mice compared with the PBS liposome-treated
controls (Fig. 4C; p#0.05). Collectively, these data illustrate that
clodronate liposome-mediated KC depletion, in two mouse
models of obesity, results in a marked reduction of hepatic TG
content and amelioration of obesity-induced hepatic steatosis.
Notably, this reduction of hepatic TGs occurs independently of
VATM depletion in the ob/ob mouse model, demonstrating the
importance of KCs in the regulation of hepatic lipid metabolism.
Clodronate liposome-mediated KC depletion decreases
hepatic lipogenic gene expression in DIO and ob/ob mice
The striking reduction of hepatic TGs in the clodronate-treated
mice could be mediated by different pathways, including increased
fatty acid oxidation, increased very-low density lipoprotein
(VLDL) secretion, reduced influx of non-esterified FFAs from
AT, and/or reduced hepatic de novo lipogenesis [32]. To assess
whether clodronate liposome treatment affected basal whole-body
metabolic parameters, mice were fed a high fat diet (HFD) for 13
weeks and subjected to metabolic cage analysis throughout the
duration of clodronate or PBS liposome treatment. We deter-
mined there were no differences in the food consumption, water
intake or physical activity between groups throughout the course
of liposome treatment (Table 1). There were also no differences in
the energy expenditure, respiratory exchange ratio, or b-hydroxy-
butyrate levels in clodronate-treated DIO mice compared with
PBS liposome-treated control mice (Table 1). Moreover, there
were no changes in serum lipoprotein concentrations (Table 1) or
expression of genes promoting fatty acid oxidation, including
peroxisome proliferator-activated receptor-a (PPARa) or carnitine
palmitoyltransferase-1a (Cpt1a) in the livers of clodronate-treated
DIO mice compared with PBS liposome-treated mice (data not
shown). These data suggest that whole body fatty acid oxidation is
not affected by clodronate-treatment in DIO mice, and therefore
we explored whether hepatic lipogenesis contributed to the
reduced hepatic TG content in the clodronate-treated mice.
Evaluation of liver samples by qRT-PCR analysis revealed
reduced expression of peroxisome proliferator-activated receptor-
c (PPARc) and downstream genes that encode lipogenic enzymes
including stearoyl-coenzyme A desaturase 1 (scd1), diacylglycerol
O-acyltransferase (dgat), fatty acid synthase (fasn), acetyl-CoA
carboxylase-2 (acc2), as well as cell death-inducing DFFA-like
effector A (cidea) that contributes to lipid droplet formation in
both DIO and ob/ob clodronate-treated mice (Fig. 5C–D; p#0.05).
Consistent with these data, a 40% decrease in Fas protein
expression was observed in the livers of the clodronate-treated
DIO mice compared with PBS-liposome treated mice (Fig. 5E–F;
p#0.05). Collectively, these data suggest that depleting KCs in the
livers of DIO and ob/ob mice is associated with decreased hepatic
steatosis, which is mediated at least, in part, by down-regulating
hepatic lipogenesis.
Clodronate liposome-mediated KC depletion reduces
hepatic inflammation in DIO and ob/ob mice
Inflammasome activation and the subsequent increase of IL-1b
in obesity have received much attention because mouse models
deficient in inflammasome components including NLR family
pyrin domain containing 3 (Nlrp3), apoptosis-associated speck-like
protein containing CARD (ASC), and caspase-1 implicate their
involvement in the progression of obesity-induced hepatic steatosis
[6,11,33,34]. To explore the underlying mechanism by which
macrophage depletion ameliorated hepatic steatosis, we analyzed
inflammatory gene expression in the livers of clodronate liposome
versus PBS liposome-treated DIO and ob/ob mice by qRT-PCR.
Consistent with macrophage depletion, we observed a 40%–75%
reduction in the mRNA expression of pro-inflammatory cytokines
TNF-a, IL-1b, IL-1a and the Nlrp3 in the livers of clodronate-
treated DIO mice (Fig. 5A; p#0.001). We observed an even more
robust 65%–72% reduction in the expression of these genes in the
livers of clodronate liposome-treated ob/ob mice compared with
PBS liposome-treated ob/ob mice (Fig. 5B; p#0.05). However, no
changes in the mRNA expression of IL-1a were observed in
clodronate-treated ob/ob mouse livers (Fig. 5B). Taken together,
these data demonstrate that clodronate-liposome mediated KC
depletion decreases the inflammatory program in steatotic livers of
obese mice.
Physiological concentrations of recombinant IL-1b
stimulate TG accumulation in isolated primary
hepatocytes
Recent reports have implicated the involvement of the Nlrp3
inflammasome in the development of hepatic steatosis [6,33,35].
Based upon the reduced Nlrp3 and IL-1b mRNA expression in
the livers of both the DIO and ob/ob clodronate-treated mice, we
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hypothesized that IL-1b might play a key role in steatosis
development in hepatocytes. We isolated primary hepatocytes
and assessed TG accumulation after 24-hour treatment with
recombinant IL-1b or PBS (Fig. 6). Microscopic evaluation
revealed a dose-dependent increase in TG accumulation with
increasing physiological doses of IL-1b as measured by Oil-Red-O
staining (Fig. 6A) [35]. To quantify the increased TG accumula-
tion we measured total hepatocyte TGs and found a 50% increase
in the recombinant IL-1b (10 ng/ml) treated hepatocytes com-
pared with untreated cells (Fig. 6D; p#0.001). Western blotting
revealed a 30% increase in Fas protein expression in the
recombinant IL-1b (10 ng/ml) treated hepatocytes compared
with untreated cells (Fig. 6B–C; p#0.05). Taken together, these
data support the hypothesis that IL-1b promotes TG accumula-
tion by upregulating de novo lipogenesis in primary hepatocytes
and is important for the pathogenesis of obesity-induced steatosis.
Pharmacological blockade of the IL-1 signaling pathway
ameliorates diet-induced steatosis in mice
The activity and signaling cascades downstream of IL-1a and
IL-1b are tightly regulated by IL-1Ra, an endogenous antagonist
of the IL-1 receptor [36,37,38]. IL-1Ra negatively regulates IL-1
signaling by binding and blocking its receptor without activation,
and mice lacking IL-1Ra has amplified steatosis compared with
wild type animals [39]. To directly determine whether pharma-
cological inhibition of IL-1 signaling has a protective effect against
Figure 2. Clodronate liposome-mediated KC and VATM depletion ameliorates hepatic steatosis in DIO mice.Wild type mice were fed a
HFD for 13 weeks and injected with 2 doses of clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 days with a 3-day interval. A.) Livers
of DIO mice were isolated, fixed in 10% formalin, embedded in paraffin, and stained with H&E or frozen in OCT and stained with Oil-Red-O to assess
steatosis. Images are representative of 12–16 animals at 10X and 20X magnification. B.) Livers of DIO animals were weighed and data is represented
as a percentage of total body weight. C.) Total TGs were extracted and normalized to tissue weight. Values represent the mean 6 SEM. An unpaired
student’s t-test was used for comparisons between groups. *P#0.05, **P#0.01.
doi:10.1371/journal.pone.0107265.g002
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NAFLD in DIO mice, we treated mice with recombinant human
IL-1Ra (Anakinra). We fed mice a HFD for 9-weeks to establish
IR and steatosis and then i.p. administered IL-1Ra (32.5 mg/kg)
or an equal volume of saline daily for the final 32 days of a 13-
week HFD. Serum recombinant human IL-1Ra levels were
increased in IL-1Ra-treated mice compared with saline-treated
mice, confirming that a physiological excess of IL-1Ra was present
in circulation (Fig. 7F; p#0.01). To confirm that IL-1Ra was
biologically active in these mice, we performed intraperitoneal
glucose tolerance tests (GTTs) 28 days after the start of injections
(Fig. 8B). Consistent with previous studies [20,21], IL-1Ra
treatment improved glucose tolerance without affecting the total
animal body weight in DIO mice (Fig. 8; p#0.05).
Upon dissection of the mice, a macroscopic reduction in the
steatotic appearance of the IL-1Ra-treated mouse livers was
observed compared with saline-treated mice (Fig. 7A–C). In
agreement with this observation, liver weights as a percentage of
body weight were reduced by approximately 20% in IL-1Ra-
treated mice compared with saline-treated mice (Fig. 7B).
Microscopic analysis of steatosis, as assessed by H&E and Oil-
Red-O staining, revealed a significant improvement in the liver
steatosis in the IL-1Ra-treated animals compared with saline-
treated controls (Fig. 7A). To quantify this improvement, we
measured total hepatic TGs and found a 30% reduction in IL-
1Ra-treated mice compared with saline-treated mice (Fig. 7C; p#
0.05). Importantly, these data demonstrate that inhibition of IL-1
Figure 3. Clodronate-encapsulated liposomes deplete KCs but not VATMs in ob/obmice. 8-week ob/obmice were injected with 2 doses of
clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. for 6 days with a 3-day interval. We observed no changes in the total animal body weight
of PBS liposome-treated mice (44.260.7 to 45.260.6) or clodronate -treated mice (41.961.4 to 41.161.7). VAT SVF was isolated and FACS analysis was
performed. A.) Upper panels, PBS liposome-treated mice. Lower panels, clodronate-treated animals. Left panels, SiglecF-negative, CD11b- and F4/80-
positive cells. Right panels, CD11c-positive cells. Panels are representative of 4–6 animals per group. B.) Percentage of the total number of cells
counted for both CD11b- and F4/80-positive cells and CD11c-positive cells in the VAT of ob/ob mice. RNA was extracted and quantitative RT-PCR was
performed for standard macrophage markers (F480, CD11c) in C.) VAT and D.) liver of ob/ob mice. Values represent the mean 6 SEM. An unpaired
student’s t-test was used for comparisons between groups. *P#0.05, ***P#0.001.
doi:10.1371/journal.pone.0107265.g003
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signaling by IL-1Ra administration in obese mice is sufficient to
reduce hepatic TG content and improve diet-induced hepatic
steatosis.
To further confirm the activity of IL-1Ra in these mice, RNA
was extracted from the livers of the IL-1Ra or saline-treated DIO
mice to evaluate the mRNA expression of pro-inflammatory
cytokines, including IL-1b and TNF-a. There was a reduction in
liver TNF-a, IL-1b, however, we observed no changes in IL-1a,
IL-6 or Nlrp3 expression in the IL-1Ra-treated mice compared
with saline-treated control mice (Fig. 7D; p#0.05). To assess
whether the improved steatosis in the IL-1Ra-treated mice was
due to altered lipid metabolism, genes involved in fatty acid
synthesis and fatty acid oxidation were analyzed. Consistent with
our previous findings in the clodronate-treated mice, reduced
expression of genes involved in fatty acid synthesis and lipogenesis
(elov6, dgat, fasn, acc2) was observed in the IL-1Ra-treated mice
compared with saline-treated control animals (Fig. 7E; p#0.05).
We observed no changes in the expression of genes related to fatty
acid oxidation, such as PPARa or Cpt1a (Fig. 7G). Taken
together, these data demonstrate that IL-1Ra administration
protects against hepatic steatosis to a similar extent as clodronate
liposome-mediated KC depletion in obese mice. Importantly,
these findings also suggest that IL-1 signaling plays a significant
role in the progression of obesity-induced steatosis by activating
the lipogenic pathway in hepatocytes.
Figure 4. Clodronate liposome-mediated KC depletion ameliorates hepatic steatosis in ob/ob mice. 8-week old male ob/ob mice were
injected with 2 doses of clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 days with a 3-day interval. A.) Livers of ob/ob animals were
isolated, fixed in 10% formalin, embedded in paraffin, and stained with H&E or frozen in OCT and stained with Oil-Red-O to assess steatosis. Images
are representative of 7–10 animals at 10X and 20X magnification. B.) Livers of ob/ob animals were weighed and data is represented as a percentage of
total body weight. C.) Total TGs were extracted and normalized to tissue weight. Values represent the mean 6 SEM. An unpaired student’s t-test was
used for comparisons between groups. *P#0.05, ***P#0.001.
doi:10.1371/journal.pone.0107265.g004
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Discussion
The key results presented here demonstrate that the macro-
phage-derived inflammatory mediator IL-1b potentiates the
hepatic manifestation of the metabolic syndrome by stimulating
lipogenesis and hepatic steatosis in obese mice (Figs. 5–7).
Utilizing clodronate liposomes to selectively deplete liver KCs in
genetically obese ob/ob mice, we report remarkable amelioration of
hepatic steatosis and significant reductions in hepatic inflamma-
tion and lipogenic gene expression (Figs. 4–5). Similar results were
obtained in the DIO model treated with clodronate liposomes
(Figs. 1–2 and 5). We also show that pharmacological blockade of
IL-1 signaling by IL-1Ra dramatically improves hepatic steatosis
by significantly decreasing inflammation and lipogenic gene
expression in DIO mouse livers (Fig. 7). Taken together, these
data indicate that inflammation not only drives liver disease
progression, but also facilitates the increased lipogenic program
and increased TG content in obese mouse livers.
Inflammation in both VAT and liver appear to play important
roles in mediating disrupted metabolism in obesity. Immune
activation and macrophage recruitment to obese AT is correlated
with systemic IR and may contribute to adipocyte dysfunction
with limited ability to sequester triglyceride and ectopic lipid
deposition [40]. Lipid-laden KCs in the liver, resulting from
increased influx of excess FFAs in circulation and increased
hepatic de novo lipogenesis, are primed to recruit immune cells
and exhibit a pro-inflammatory phenotype that exacerbates
hepatic inflammation and TG accumulation, thus promoting
obesity-induced steatosis and NAFLD [41]. However, the specific
role of KCs in obesity-induced hepatic steatosis remains unclear
because the authors of numerous studies on this point have come
to contradictory conclusions [12,22,24,28]. For example, Bu et al,
administered clodronate liposomes by i.p. as a preventative
treatment against DIO and reported protection against diet-
induced steatosis; however, the data show robust decreases in
VATM content, but only modest reductions in KC content in the
livers of clodronate-treated DIO mice [28]. The use of CD11c-
diptheria toxin transgenic mice to deplete macrophages in AT
revealed normalization of insulin sensitivity in obese mice;
however, this method also did not alter KCs in the liver [9].
Feng and colleagues reported significant improvements in obesity-
induced steatosis with marked reductions in VATM and KC
content in clodronate liposome-treated DIO mice [12]. On the
contrary, Clemente, et al reported significant increases in both
hepatic TG and VATM content in DIO mice treated with
clodronate liposomes by i.p., and Lanthier, et al reported
significant reductions in KCs without changes to the hepatic TG
or VATM contents after intravenous clodronate liposome
administration in DIO mice [22,24]. Thus, the differences in
methods used amongst these studies, including dissimilar admin-
istration routes, inconsistent injection timelines, varied diets and
feeding schedules, and inconsistent clodronate concentrations have
confounded our understanding of the role of KCs in hepatic lipid
metabolism.
We approached this problem by studying both a DIO mouse
model and a genetic mouse model of obesity. Our studies
presented here on the ob/ob mouse, which responded to the
clodronate treatment with selective KC depletion without
macrophage cell depletion in VAT or SAT, was particularly
insightful (Fig. 3). This selectivity of macrophage depletion of KCs
but not VATMs in the ob/ob mouse may relate to an impaired
ability of AT macrophages from ob/ob mice to take up liposomes.
Li et al demonstrated that lipid-laden macrophages from the
peritoneum and atherosclerotic lesions of ob/ob mice have an
impaired ability to clear apoptotic cells, suggesting a generalized
defect in the phagocytic ability of ob/ob macrophages [42].
Additionally, clodronate preferentially depletes F4/80high
CD11blow macrophages, consistent with the expression profile of
Table 1. Depletion of macrophages with clodronate-encapsulated liposomes improves fasting glycemia and insulin levels in DIO
and ob/ob mice with no changes in the metabolic profile.
Metabolic Parameter PBS (DIO)
Clodronate
(DIO)
PBS
(ob/ob)
Clodronate
(ob/ob)
FBG (mg/dL) 235611.9 **171611.1 404629.6 **256620.0
Fasting Insulin (ng/mL) 2.060.3 *0.760.1 6.660.5 *3.961.0
FFAs (mmol/L) 0.3060.02 *0.4060.08 0.5260.03 0.4160.09
TGs (mg/dL) 56.6617.8 61.5613.9 32.265.1 **67.569.8
Cholesterol (mg/dL) 131618.5 151628.8 N.A. N.A.
HDL (mg/dL) 121611.3 138619.1 N.A. N.A.
LDL (mg/dL) 1262.4 2168.6 N.A. N.A.
B-hydroxybutyrate (uM) 0.360.02 0.2760.04 N.A. N.A.
Food Intake (g/day) 2.6760.17 2.5160.21 N.A. N.A.
Water Intake (g/day) 1.7860.07 1.6860.11 N.A. N.A.
Total Activity (counts/day: 24 hr) 32906381 3165695 N.A. N.A.
VO2 (ml/hr/kg: 24 hr) 48386120 4759678 N.A. N.A.
VCO2 (ml/hr/kg: 24 hr) 37236114 3650661 N.A. N.A.
EE (ml/hr/kg: 24 hr) 23.1860.60 23.0560.33 N.A. N.A.
RER (ml/hr/kg: 24 hr) 0.77160.01 0.7596.00 N.A. N.A.
Wild type mice fed a HFD for 13 weeks or 8-week ob/ob mice were injected with 2 doses of clodronate liposomes (250 mg/kg) or PBS liposomes i.p. for 6 days with a 3-
day interval. Data is representative of 12–16 DIO and 7–10 ob/ob animals. DIO mice were housed in metabolic cages prior to treatment for baseline analysis. Animals
were housed in metabolic cages until completion of the experiment. EDTA plasma was drawn from the retro orbital sinus for serum analysis. Metabolic cage data is
representative of 4–6 animals. Values represent the mean 6 SEM. An unpaired student’s t-test was used for comparisons between groups. *p#0.05, **#0.01.
doi:10.1371/journal.pone.0107265.t001
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KCs, whereas clodronate does not effectively deplete F4/80low
CD11bhigh macrophages from other tissues or in systemic
circulation [43,44]. For these reasons, by utilizing the ob/ob
mouse, we were able to characterize the metabolic consequences
of selective KC depletion in the absence of generalized macro-
phage depletion in other tissues. Thus, the striking improvement of
obesity-induced hepatic steatosis in the clodronate-treated ob/ob
mice reveals a profound regulation by KCs on hepatic lipid
metabolism.
Our data also revealed remarkable improvements in obesity-
induced hepatic steatosis with reductions in liver weight and
hepatic TG content in the clodronate-treated DIO mice when
compared with PBS liposome-treated control animals (Fig. 2). A
recent report by Bu et al suggests that this clodronate liposome-
Figure 5. Clodronate liposome-mediated KC depletion in DIO and ob/ob mice significantly reduces hepatic expression of genes
involved in inflammation and lipogenesis. Wild type mice fed a HFD for 13 weeks or 8-week ob/ob mice were injected with 2 doses of
clodronate liposomes (250 mg/kg) or PBS liposomes by i.p. over 6 days with a 3-day interval. Data is representative of 12–16 DIO and 7–10 ob/ob
animals. Liver was isolated, RNA was extracted and subjected to quantitative RT-PCR for inflammatory (TNF-a, IL-1b, IL-1a, IL-6, Nlrp3) and lipogenic
(Fasn, Acc2, Dgat, Scd1, Elov6, PPARc, Cidea) gene expression in A,C.) DIO and B,D) ob/obmice. E.) Protein was extracted from the livers of DIO animals
and Western blot analysis was performed to detect Fas expression. PBS and Clodronate samples are from the same film, cut due to sample separation.
F.) Relative densitometry from E. Values represent the mean6 SEM. An unpaired student’s t-test was used for comparisons between groups. *P#0.05,
***P#0.001.
doi:10.1371/journal.pone.0107265.g005
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induced reduction of hepatic TGs in DIO mice is dependent upon
VATM depletion [28]. In our study, cell depletion due to
clodronate liposomes was observed for both KC and VATMs in
the DIO mouse model (Figs. 1–2), precluding a specific interpre-
tation regarding which pool of cells may be responsible for the
metabolic effects observed in this mouse model. However, our
results in the ob/ob mouse showing a selective KC effect on hepatic
lipids suggests that KCs may also drive liver TG accumulation in
the DIO model, and that both KCs and VATMs are important in
modulating obesity-induced hepatic steatosis.
The hallmark of NAFLD is the excessive accumulation of TG in
hepatocytes caused by alterations in hepatic lipid metabolism.
Mechanisms contributing to excessive hepatic TG accumulation in
obesity are disruptions in lipid disposal via b-oxidation or VLDL
secretion, but primarily due to enhanced hepatic de novo
lipogenesis and increased delivery of circulating FFAs to the liver
[45]. Increased lipolysis of expanded AT and the consequent rise
in circulating FFAs account for 60% of the hepatic TGs in obese
patients presenting with NAFLD [46]. Clodronate liposome-
treatment reduced VATM content in DIO mice, and these mice
present with increased circulating FFAs (Fig. 1A–C, Table 1).
These data are consistent with Kosteli, et al. demonstrating that
macrophage cell depletion in VAT leads to increased expression of
the TG lipase ATGL and increased lipolysis in mice [47]. We
report no changes in circulating FFAs in clodronate-treated ob/ob
mice, and deem this to be due to the inability to deplete VATMs
in this model; however, these mice exhibit increased circulating
TGs (Fig. 3A–C, Table 1). Importantly, the rise in circulating
FFAs in clodronate-treated DIO mice is accompanied by
remarkable hepatic TG clearance without changes in the
cholesterol profile, circulating ketones, or energy expenditure
when the mice are subjected to metabolic cage analysis (Fig. 2,
Table 1). Using a multiple-stable-isotope approach, Donnelly et al.
estimated de novo lipid synthesis accounts for 30% of the hepatic
TG content in NAFLD patients [32]. We report reduced
expression of genes related to de novo hepatic lipogenesis (Fasn,
Acc2, Dgat, Scd1) in both DIO and ob/ob clodronate-treated mice
(Fig. 5C–F). Consistent with our data, the liver-specific Scd1
knockout (KO) mice are protected from obesity-induced hepatic
steatosis, while exhibiting reduced rates of hepatic fatty acid
synthesis and decreased expression of key lipogenic enzymes (Fasn
and Acc1/2) [48]. Mao, et al generated liver-specific Acc1 KO
mice with decreased rates of de novo lipogenesis, however a
compensatory up regulation of Acc2 occurred in other studies
utilizing these mice [49,50]. Inhibition of Acc1/Acc2 by antisense
oligonucleotides reversed diet-induced hepatic steatosis in mice
[49,50,51]. Collectively, our data suggests that the clearance of
hepatic TGs after clodronate liposome-mediated KC depletion in
the livers of obese mice is associated with decreased hepatic
steatosis which is mediated, at least in part, by down regulating
hepatic de novo lipogenesis.
Obese humans that present with NAFLD have increased
circulating and hepatic levels of TNF-a, IL-1b, IL-6 and other
acute phase proteins when compared with lean control subjects
[7,18,52]. KC depletion significantly reduced hepatic gene
expression of these pro-inflammatory cytokines in both clodro-
nate-treated DIO and ob/ob mice (Fig. 5A–B). We also report
decreased Nlrp3 expression, an essential inflammasome compo-
nent that is necessary for caspase-1 activation and IL-1b release, in
both clodronate-treated DIO and ob/ob mice compared with PBS
Figure 6. Physiological concentrations of IL-1b elicit a biological response in primary mouse hepatocytes to increase TG
accumulation and lipogenic gene expression. Primary hepatocytes from wild type mice were isolated via perfusion, stimulated with the
indicated doses of recombinant mouse IL-1b and evaluated after 24-hours. A.) Cells were fixed in 10% formalin and stained with Oil-Red-O to assess
TG accumulation. B.) Fas expression was analyzed in primary hepatocyte cell lysates after a 24-hour stimulation with the indicated doses of
recombinant IL-1b and normalized to b-actin. C). Relative densitometry from B. D.) TGs were extracted and measured after a 24-hour stimulation with
recombinant IL-1b (10 ng/mL) and normalized to the amount of total protein. The data are representative of 4 experiments. All stimulations were
performed in duplicate. Values represent the mean6 SEM. A paired student’s t-test was used for comparisons between groups *P#0.05, ***P#0.001.
doi:10.1371/journal.pone.0107265.g006
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liposome-treated controls (Fig. 5A–B). Our data show no changes
in the gene expression of inflammasome-independent cytokine, IL-
1a, in clodronate-treated ob/ob mouse livers (Fig. 5B). Even
though clodronate-mediated KC depletion improves hepatic
steatosis in both models, we only observe a decrease in IL-1a
expression in clodronate-treated DIO mouse livers compared with
control mice (Fig. 5A). Adoptive transfer experiments reveal that
IL-1a is a hepatocyte-derived cytokine, rather than from KCs or
recruited bone marrow-derived cells in obese mice [53,54].
Furthermore, IL-1a and IL-1b are expressed at different phases
of the inflammatory response and are derived from different cell
types, suggesting that they may have distinct biological roles [55].
Figure 7. Pharmacological intervention via inhibition of IL-1 signaling ameliorates diet-induced steatosis in DIO mice.Wild type mice
were fed a HFD for 13 weeks. At 32 days prior to sacrifice, mice were started on daily injections of IL-1Ra (Anakinra; 32 mg/kg) or saline by i.p
administration. Data are representative of 10 mice per group. A.) Livers were isolated, fixed in 10% formalin, embedded in paraffin, and stained with
H&E or frozen in OCT and stained with Oil-Red-O to assess steatosis. B.) Livers were isolated, weighed and represented as a percentage of total animal
body weight. C.) Total TGs were extracted and normalized to tissue weight. RNA was extracted and subjected to quantitative RT-PCR for expression of
genes involved in D.) inflammation (TNF-a, IL-1b, IL-1a, IL-6, Nlrp3), E.) lipogenesis (Fasn, Acc2, Dgat, Scd1, Elov6, PPARc, Cidea) and G.) fatty acid
oxidation (PPARa, Cpt1a). F.) EDTA plasma was drawn via the retro orbital sinus and serum was analyzed for IL-1Ra by ELISA. Values represent the
mean 6 SEM. An unpaired student’s t-test was used for comparisons between groups *P#0.05, **P#0.01.
doi:10.1371/journal.pone.0107265.g007
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Additionally, IL-1b KO mice are protected from diet-induced
steatosis, whereas IL-1a KO mice develop steatosis [53]. Although
in our studies we cannot discount IL-1a involvement, we
hypothesize that it does not play a role in obesity-induced hepatic
steatosis development. Thus, the decreases in hepatic inflamma-
tion after clodronate liposome-mediated KC depletion suggest that
inflammasome activation required to increase IL-1b production
from KCs is important for obesity-induced hepatic inflammation.
IL-1b rapidly increases hepatic lipid accumulation in vivo by
acutely increasing the rates of hepatic fatty acid synthesis [34,56].
To further address the steatogenic potential of IL-1b, we assessed
whether IL-1b would increase hepatic TG accumulation in a cell
autonomous manner. IL-1b treatment increased TG accumula-
tion and expression of the key lipogenic enzyme, Fas, in primary
hepatocytes (Fig. 6). In agreement with the decreased hepatic
inflammation observed in clodronate-treated mice, caspase-1-
deficient mice (that lack IL-1b expression) exhibit attenuated diet-
induced hepatic steatosis and significant decreases in hepatic
lipogenic gene expression compared with wild type control mice
[33]. These data suggest that IL-1b influences hepatocyte lipid
metabolism in obese mice by stimulating the de novo lipogenesis
pathway to drive hepatic TG accumulation. However, Stienstra
and colleagues suggested that IL-1b-mediated suppression of
hepatic PPARa and fatty acid oxidation was responsible for
hepatic lipid accumulation in obesity [57]. We report no changes
in the respiratory exchange ratio, oxygen consumption or
circulating b-hydroxybutyrate levels in clodronate-treated DIO
mice compared with PBS liposome-treated mice, suggesting
functional hepatic fatty acid oxidation in our clodronate-treated
DIO mice (Table 1).
The inflammatory response associated with obesity arises from
an activation of the innate immune system, concurrently
increasing anti-inflammatory cytokines to neutralize these pro-
inflammatory changes. IL-1Ra, a naturally occurring antagonist of
IL-1 signaling, is released as an acute phase protein and is
produced by hepatocytes, macrophages/monocytes, and even
adipocytes to balance the inflammatory effects of IL-1a/b
[39,58,59]. Circulating IL-1Ra positively correlates with obesity,
and IL-1Ra KO mice exhibit a dramatic exacerbation of hepatic
steatosis [39,60]. Pioglitazone, an oral anti-diabetic drug, decreas-
es hepatic steatosis and attenuates the subclinical inflammation in
NAFLD patients; however prominent side effects include in-
creased adiposity and weight gain [61,62]. Anakinra, also used as a
therapeutic in obese, diabetic patients, improves pancreatic islet
function and glucose tolerance, but has not been studied in the
context of NAFLD [18]. We demonstrated here that pharmaco-
logical blockade of IL-1 signaling by IL-1Ra administration is
sufficient to improve hepatic steatosis and the metabolic profile in
DIO mice (Figs. 7–8). Daily IL-1Ra administration to DIO mice
significantly improved glucose tolerance as detected by GTT
without changes to the total animal body weight (Fig. 8A–D).
Collectively, we report a significant improvement in obesity-
induced steatosis as assessed by hepatic Oil-Red-O staining,
decreased liver weight and reductions in the hepatic TG content of
IL-1Ra-treated mice compared with saline-treated control mice
(Fig. 7A–C). The expression of pro-inflammatory cytokines and
genes involved in fatty acid synthesis (Fasn, Dgat, Scd1) are
reduced significantly in the livers of IL-1Ra-treated mice, thus
confirming our findings in the clodronate-treated DIO and ob/ob
mouse models (Fig. 5 and Fig. 7D–E). Importantly, inhibition of
IL-1 signaling did not affect fatty acid oxidation gene expression
(PPARa and Cpt1a) (Fig. 7G). These data suggest that inhibition
of IL-1 signaling by IL-1Ra administration is sufficient to improve
obesity-induced hepatic steatosis, in part, by decreasing hepatic
lipogenic gene expression and TG accumulation in DIO mouse
livers.
In summary, our findings demonstrate that KC depletion in two
mouse models of obesity markedly reduces hepatic inflammation
and obesity-induced steatosis. With selective depletion of KCs in
Figure 8. Pharmacological intervention via inhibition of IL-1
signaling improves the glucose tolerance in DIO mice. Wild type
mice were fed a HFD for 13 weeks. At 32 days prior to sacrifice, mice
were started on daily injections of IL-1Ra (Anakinra; 32 mg/kg) or saline
by i.p. administration. Data are representative of 10 mice per group. At
the end of 13 weeks, Anakinra-treated mice displayed no changes in A.)
total animal body weight and were more glucose tolerant as
demonstrated by a reduction in B.) area under the curve (AUC) for
the intraperitoneal GTT and C.) fasting insulin levels. Values represent
the mean 6 SEM. An unpaired student’s t-test was used for
comparisons between groups. *P#0.05, **P#0.01.
doi:10.1371/journal.pone.0107265.g008
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the ob/ob mouse, our data suggests that this improvement in
hepatic steatosis is independent of VATM depletion, and that KCs
and KC-derived cytokines, including IL-1b are important for
hepatic metabolism regulation. Our data also suggests that the
significant reduction in hepatic TGs observed in both clodronate-
treated DIO and ob/ob mice is mediated, in part, by down
regulating hepatic inflammation and de novo lipogenesis. Addi-
tionally, we report that inhibition of IL-1 signaling by adminis-
tration of IL-1Ra markedly improves hepatic steatosis in DIO
mice by significantly reducing hepatic inflammation and lipogenic
gene expression. Therefore, the results herein suggest that IL-1b
signaling mediates hepatocyte TG accumulation by driving the
de novo lipogenic signaling pathway in obese mouse livers and that
IL-1b represents a promising therapeutic target in the treatment of
obesity-induced NAFLD.
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